Skip to main content
Premium Trial:

Request an Annual Quote

Definiens, Cernostics Team on Multiplex Cancer Tests

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Definiens and Cernostics today announced that they will collaborate on the development of multiplex molecular diagnostics tests for a variety of cancers.

Danville, Pa.-based Cernostics will use Definiens' Tissue Studio digital pathology technology to develop the tests. The Definiens technology enables pathologists to analyze cancers on the cellular and sub-cellular level, the firms said.

"The collaboration with Definiens will enable Cernostics to accelerate development of its pipeline of systems biology-based diagnostic, prognostic and predictive tests," Cernostics CEO Michael Hoerres said in a statement.

Terms of the alliance were not disclosed.

Last year, Cernostics teamed up with Geisinger Health Systems to develop diagnostics for detecting cellular and molecular differences in patient tissue samples.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.